Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations

Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly applic...

Descripción completa

Detalles Bibliográficos
Autores principales: Soyka, Michael, Franke, Andreas G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474991/
https://www.ncbi.nlm.nih.gov/pubmed/34631459
http://dx.doi.org/10.5498/wjp.v11.i9.543
_version_ 1784575343803236352
author Soyka, Michael
Franke, Andreas G
author_facet Soyka, Michael
Franke, Andreas G
author_sort Soyka, Michael
collection PubMed
description Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade™) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine™]. The pharmacology, clinical efficacy and prospects of these medications are discussed.
format Online
Article
Text
id pubmed-8474991
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-84749912021-10-08 Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations Soyka, Michael Franke, Andreas G World J Psychiatry Minireviews Oral methadone or sublingual buprenorphine are first-line medications for pharmacotherapy of opioid use disorders (OUDs). Three long-acting buprenorphine depot or implant formulations are currently available for the treatment of OUDs: (1) CAM 2038 (Buvidal) for subcutaneous weekly and monthly application; (2) RBP-6000 (Sublocade™) as a monthly depot formulation; and (3) A six-month buprenorphine implant [Probuphine™]. The pharmacology, clinical efficacy and prospects of these medications are discussed. Baishideng Publishing Group Inc 2021-09-19 /pmc/articles/PMC8474991/ /pubmed/34631459 http://dx.doi.org/10.5498/wjp.v11.i9.543 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Soyka, Michael
Franke, Andreas G
Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
title Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
title_full Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
title_fullStr Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
title_full_unstemmed Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
title_short Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
title_sort recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474991/
https://www.ncbi.nlm.nih.gov/pubmed/34631459
http://dx.doi.org/10.5498/wjp.v11.i9.543
work_keys_str_mv AT soykamichael recentadvancesinthetreatmentofopioidusedisordersfocusonlongactingbuprenorphineformulations
AT frankeandreasg recentadvancesinthetreatmentofopioidusedisordersfocusonlongactingbuprenorphineformulations

Ejemplares similares